Christopher Haqq

Filings by Christopher Haqq span 3 companies, the busiest being Atara Biotherapeutics, Inc., Elicio Therapeutics, Inc. and Surrozen, Inc./DE. The record holds 75 filings, for trades running from 16 January 2015 to 2 February 2026.

No open-market purchase appears, only 50 sales worth €6.6M. Outside the open market, there are 12 share grants and 13 option exercises.

On 3 February 2026 came the latest disclosure, a share grant in Elicio Therapeutics, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.